Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS Texas Oxycodone ER Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - TexasPolicy N/A

    Oxycodone Extended-Release Agents

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - Texas policy alerts

    Know when Blue Cross Blue Shield - Texas releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization for low-dose oxycodone extended-release products in Texas, requiring a qualifying cancer, antineoplastic-treatment, or chronic nonmalignant pain history and a quantity of no more than 3 units per day.

    Policy Summary
    PayerBlue Cross Blue Shield - Texas
    PolicyOxycodone Extended-Release Agents
    Policy CodePolicy N/A
    Change TypeSupporting-table coding updateno material clinical or coverage change
    Effective DateOct 1, 2025
    Last ReviewJun 10, 2024
    Next Review DateN/A
    Key ActionSubmit evidence of at least one qualifying pathway and document a requested quantity of no more than 3 units per day.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3/dayMaximum quantity
    365 daysApproval duration
    730 daysCancer diagnosis look-back
    365 daysTherapy or CNMP look-back
    15

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Listed oxycodone ER entries

    Coverage Criteria

    Low-dose oxycodone ER initial approval

    Covered when at least one qualifying clinical pathway is met and the requested quantity is no more than 3 units per day.

    Low-dose oxycodone ER approval

    • Qualifying clinical history

      • Malignant cancer pathway: The client has a diagnosis of malignant cancer in the last 730 days.Look-back: 730 days
      • Antineoplastic-agent pathway: The client has a history of an antineoplastic agent in the last 365 days.Look-back: 365 days
      • Chronic nonmalignant pain pathway: The client has a diagnosis of CNMP in the last 365 days.Look-back: 365 days
    • Quantity requirement: The request is for no more than 3 units per day.≤ 3 units/day

    Step 1: Diagnosis of malignant cancer

    Covered for this authorization step when the diagnosis requirement is met.

    Malignant cancer diagnosis requirement: At least 1 diagnosis from the listed Malignant Cancer Diagnosis Codes must be documented.1 diagnosis within the prior 730 days

    The diagnosis must be represented by one of the listed malignant cancer ICD-10 codes.

    Step 1: Diagnosis of malignant cancer

    Covered for Step 1 when the diagnosis requirement is met.

    Step 1 malignant cancer diagnosis: At least 1 diagnosis from the Malignant Cancer Diagnosis Codes list must be documented within the look-back timeframe.1 diagnosis; 730 days

    Malignant cancer diagnosis

    Covered when the required diagnosis criterion is met.

    Malignant cancer diagnosis: At least one diagnosis from the listed malignant cancer ICD-10 codes must be documented.1 diagnosis within the prior 730 days

    Step 1: Malignant cancer diagnosis

    Covered authorization pathway when the following Step 1 requirement is met.

    Step 1 malignant cancer diagnosis: At least 1 diagnosis must be documented from the listed malignant cancer ICD-10 codes.1 diagnosis within 730 days

    Malignant cancer diagnosis

    Step 1 requires the following diagnosis criterion.

    Step 1 diagnosis requirement: At least 1 malignant cancer diagnosis from the listed ICD-10 codes must be documented within the 730-day look-back timeframe.1 diagnosis; 730 days

    Step 1: Diagnosis of malignant cancer

    Step 1 requires a diagnosis of malignant cancer.

    Step 1 malignant cancer diagnosis

    • Diagnosis timing: The qualifying diagnosis must have been recorded within the look-back period.730 days

    Antineoplastic agent initial authorization

    Covered when the criteria steps are met.

    Antineoplastic-agent authorization

    • Step 1: diagnosis of malignant cancer: The patient has a malignant cancer diagnosis represented by one of the listed ICD-10 codes.
    • Step 2: history of an antineoplastic agent: The patient has a history of at least one listed antineoplastic agent.1 agent within 365 days

    Step 2: history of an antineoplastic agent

    Covered when the Step 2 requirement is met.

    Step 2 antineoplastic-agent history: At least one qualifying antineoplastic agent must be identified in the member's history.1 agent within 365 days

    Step 3: diagnosis of CNMP

    Covered when the Step 3 requirement is met.

    Step 3 CNMP diagnosis: At least one diagnosis from the listed CNMP ICD-10 diagnosis codes must be present.1 diagnosis within 365 days

    Step 2: History of an antineoplastic agent

    Step 2 requires one qualifying diagnosis within the 365-day look-back timeframe.

    Step 2 diagnosis-history requirement: The case must include a qualifying diagnosis from the Step 2 history-of-antineoplastic-agent diagnosis list.1 diagnosis; 365 days

    Step 3: Diagnosis of CNMP

    Step 3 requires one qualifying CNMP diagnosis within the 365-day look-back timeframe.

    Step 3 CNMP diagnosis requirement: The case must include one diagnosis from the Step 3 CNMP diagnosis-code list, documented within the 365-day look-back timeframe.1 diagnosis; 365 days

    Step 3 CNMP diagnosis

    Covered for Step 3 diagnosis verification when the required diagnosis condition is met.

    Step 3 diagnosis of CNMP: At least one CNMP diagnosis code listed in the policy must be documented.1 qualifying diagnosis within 365 days

    Step 3: qualifying CNMP diagnosis

    Covered when the Step 3 diagnosis requirement is met.

    Step 3 CNMP diagnosis: At least 1 diagnosis code from the qualifying CNMP diagnosis list must be documented within the 365-day look-back timeframe.1 qualifying diagnosis; 365 days

    Step 3: qualifying CNMP diagnosis

    Step 3 requires at least 1 CNMP diagnosis.

    Step 3 CNMP diagnosis: At least one diagnosis from the listed CNMP ICD-10 diagnosis-code set must be documented.1 qualifying diagnosis within 365 days

    Step 3 diagnosis of CNMP

    Step 3 requires one qualifying CNMP diagnosis documented within the lookback period.

    Step 3 CNMP diagnosis: At least one diagnosis must be documented using a listed CNMP ICD-10 code within the 365-day lookback timeframe.1 diagnosis; 365 days

    Step 3 diagnosis requirement

    Step 3 diagnosis of CNMP.

    Step 3 CNMP diagnosis: At least one qualifying CNMP diagnosis code must be present and documented within the prior 365 days.1 diagnosis; 365-day lookback

    Covered Products and Diagnosis Codes

    Drugs requiring prior authorizationNDC
    No codes listed
    Step 1: malignant cancer diagnosis codesICD-10Covered
    No codes listed
    Malignant Cancer Diagnosis CodesICD-10Covered
    No codes listed
    Malignant Cancer Diagnosis CodesICD-10Covered
    No codes listed
    Malignant Cancer Diagnosis CodesICD-10
    No codes listed
    Malignant Cancer Diagnosis CodesICD-10
    No codes listed
    Malignant Cancer Diagnosis CodesICD-10
    No codes listed
    Malignant Cancer Diagnosis CodesICD-10
    No codes listed
    Malignant Cancer Diagnosis CodesICD-10
    No codes listed
    Malignant Cancer Diagnosis CodesICD-10
    No codes listed
    Malignant Cancer Diagnosis CodesICD-10
    No codes listed
    Malignant Cancer Diagnosis CodesICD-10
    No codes listed
    Malignant Cancer Diagnosis CodesICD-10
    No codes listed
    Malignant Cancer Diagnosis CodesICD-10
    No codes listed
    Malignant Cancer Diagnosis CodesICD-10Covered
    No codes listed
    Malignant Cancer Diagnosis CodesICD-10Covered
    No codes listed
    Malignant Cancer Diagnosis CodesICD-10Covered
    No codes listed
    Malignant Cancer Diagnosis CodesICD-10Covered
    No codes listed
    Antineoplastic AgentsGCNCovered
    No codes listed
    Antineoplastic Agents and Step-2 History AgentsGCNCovered
    No codes listed
    Step 2 antineoplastic-agent history products and GCNsmixed
    No codes listed
    CNMP diagnosis codesICD-10Covered
    No codes listed
    Step 2 history-of-antineoplastic-agent diagnosis codesICD-10
    No codes listed
    Step 3 CNMP diagnosis codesICD-10Covered
    No codes listed
    CNMP Diagnosis CodesICD-10Covered
    No codes listed
    CNMP diagnosis codes: cranial and facial nerve disordersICD-10Covered
    No codes listed
    CNMP diagnosis codes: nerve root, plexus, and peripheral nerve disordersICD-10Covered
    No codes listed
    CNMP diagnosis codes: neuropathy, cerebral palsy, paralysis, and spinal cord syndromesICD-10Covered
    No codes listed
    CNMP diagnosis codes: chronic pain and autonomic disordersICD-10Covered
    No codes listed
    CNMP diagnosis codes: central nervous system, spinal cord, and autonomic disordersICD-10Covered
    No codes listed
    CNMP diagnosis codes: atherosclerotic leg and bypass-graft disease with ulcerationICD-10Covered
    No codes listed
    CNMP Diagnosis Codes – vascular and lymphadenitis diagnosesICD-10Covered
    No codes listed
    CNMP Diagnosis Codes – pressure ulcersICD-10Covered
    No codes listed
    CNMP Diagnosis CodesICD-10Covered
    No codes listed
    CNMP diagnosis codes — foot ulcersICD-10
    No codes listed
    CNMP diagnosis codes — lower-leg ulcersICD-10
    No codes listed
    CNMP diagnosis codes — other chronic ulcersICD-10
    No codes listed
    CNMP diagnosis codes — staphylococcal arthritisICD-10
    No codes listed
    CNMP diagnosis codes — pneumococcal arthritisICD-10
    No codes listed
    CNMP diagnosis codes — other streptococcal arthritisICD-10
    No codes listed
    CNMP diagnosis codes — other bacterial and pyogenic arthritisICD-10
    No codes listed

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for the listed low-dose oxycodone extended-release products and strengths. Submit the requested product, strength, and supporting clinical documentation for review.

    • Oxycodone HCl 10 mg, 20 mg, and 40 mg tablets ER
    • Oxycodone HCl ER 15 mg and 30 mg tablets
    • OxyContin 10 mg, 15 mg, 20 mg, 30 mg, and 40 mg tablets
    • Xtampza ER 9 mg, 13.5 mg, 18 mg, 27 mg, and 36 mg capsules
    • Approved requests are authorized for 365 days
    Documentation Required

    Step 1: Document a Recent Malignant Cancer Diagnosis

    Document one qualifying malignant cancer diagnosis within the preceding 730 days. The diagnosis must be supported by one of the malignant cancer ICD-10 codes listed in the policy tables.

    Initial Authorization Pathways

    Low-dose oxycodone ER initial therapy

    Initial approval follows an OR pathway for qualifying history, followed by a required daily quantity limit.

    Initial therapy

    • Qualifying pathway: Malignant cancer within 730 days, antineoplastic-agent history within 365 days, or CNMP within 365 days.
    • Dose limit: Requested quantity is no more than 3 units per day.≤ 3 units/day

    Initial authorization diagnosis requirement

    Step 1 diagnosis prerequisite.

    Sequential Therapy Requirements

    StepRequirementLook-back timeframeCoverage
    1History of at least 1 antineoplastic agent365 daysCovered when the requirement is met
    StepRequirementLook-back timeframeCoverage
    2Document history of at least one listed antineoplastic agent365 daysCovered when the requirement is met
    StepRequirementLook-back timeframeCoverage
    3Document at least one listed CNMP diagnosis365 daysCovered when the requirement is met

    Quantity Limit

    Quantity Limits
    Product categoryOxycodone extended-release agents low dose
    Maximum quantity≤ 3 units/day
    If quantity is within limitApprove for 365 days
    If quantity exceeds limitDeny
    Policy Summary
    PayerBlue Cross Blue Shield - Texas
    PolicyOxycodone Extended-Release Agents
    Policy CodePolicy N/A
    Change TypeSupporting-table coding updateno material clinical or coverage change
    Effective DateOct 1, 2025
    Last ReviewJun 10, 2024
    Next Review DateN/A
    Key ActionSubmit evidence of at least one qualifying pathway and document a requested quantity of no more than 3 units per day.
    SourceLink
    On This Page
    Coverage CriteriaCovered Products and Diagnosis CodesAuthorization and Documentation RequirementsInitial Authorization PathwaysSequential Therapy RequirementsQuantity Limit
    CNMP diagnosis codes — direct joint infectionICD-10
    No codes listed
    • Required diagnosis: 1
    • Look-back period: 730 days
    • Include the diagnosis code, description, and date of service
    • A recent malignant cancer diagnosis is sufficient for Step 1 and may route the request directly to quantity review
    Denial Risk

    Step 1 Denial Risk: No Qualifying Cancer Diagnosis

    If no qualifying cancer diagnosis is established, the request must proceed to Step 2. Failure to document a listed malignant cancer diagnosis within the 730-day look-back period may result in denial or require review under the subsequent authorization steps.

    • Use only the listed malignant cancer ICD-10 codes
    • Do not rely on an undated, outdated, or nonqualifying diagnosis
    • Document the diagnosis and service date in the prior authorization submission
    Documentation Required

    Step 2: Document Prior Antineoplastic-Agent History

    When Step 1 is not met, document a history of at least one qualifying antineoplastic agent within the preceding 365 days. The therapy must appear in the policy’s antineoplastic-agent list and meet the required quantity of 1.

    • Required quantity: 1
    • Look-back period: 365 days
    • Submit the antineoplastic agent name, GCN or other identifying information, fill or administration date, and quantity
    • Prior antineoplastic-agent history may route the request to Step 4 when documented
    Denial Risk

    Step 2 Denial Risk: Missing Prior Therapy Documentation

    A request may fail if the required prior antineoplastic-agent history is missing, cannot be verified, falls outside the 365-day look-back period, or does not meet the required quantity of 1. Document both the prior therapy and the qualifying diagnosis history when applicable.

    • Use the antineoplastic agents listed in the policy tables
    • Provide pharmacy or medical-record evidence of therapy
    • Do not substitute an unlisted agent or an undocumented treatment history
    Documentation Required

    Step 3: Document One Qualifying CNMP Diagnosis

    If neither a qualifying malignant cancer diagnosis nor qualifying antineoplastic-agent history is established, document one qualifying CNMP diagnosis from the policy’s ICD-10 list within the preceding 365 days.

    • Required diagnosis: 1
    • Look-back period: 365 days
    • Include the qualifying CNMP ICD-10 code, description, and date of service
    • Use the listed CNMP diagnoses, including qualifying chronic pain, neurologic, hematologic, vascular, ulcer, and related conditions in the policy tables
    Denial Risk

    Step 3 Denial Risk: CNMP Diagnosis Not Established

    Step 3 may fail when the submitted diagnosis is not on the listed CNMP ICD-10 code set, is not documented, or is outside the 365-day look-back period. Submit one qualifying diagnosis with supporting clinical records.

    • Document the diagnosis and date of service
    • Ensure the code corresponds to the diagnosis description in the policy table
    • An absent, outdated, or nonqualifying CNMP diagnosis may result in denial
    Step Therapy

    Sequential Authorization Steps and Requested Daily Quantity

    The authorization pathway is sequential: Step 1 malignant cancer diagnosis, then Step 2 prior antineoplastic-agent history, then Step 3 CNMP diagnosis. If any applicable step is satisfied, proceed to Step 4; if none is satisfied, the request is denied.

    • Step 1: one listed malignant cancer diagnosis within 730 days
    • Step 2: one qualifying antineoplastic-agent history within 365 days
    • Step 3: one listed CNMP diagnosis within 365 days
    • Step 4: requested quantity must be ≤ 3 units per day
    • Quantity greater than 3 units per day is denied
    • Quantity of ≤ 3 units per day is approved for 365 days when a preceding authorization step is met
    Qualifying malignant cancer diagnosis:
    The member must have at least 1 qualifying malignant cancer diagnosis code from the listed ICD-10 codes within the prior 730 days.
    1 diagnosis within 730 days

    Initial therapy diagnosis requirement

    Initial authorization requires the diagnosis criterion below.

    Qualifying malignant cancer diagnosis: The member has at least one listed malignant cancer diagnosis documented within the prior 730 days.1 diagnosis; 730-day look-back

    Initial therapy: qualifying malignancy

    Step 1.

    Malignant cancer diagnosis: The patient has at least 1 diagnosis represented by the listed malignant cancer ICD-10 codes.Diagnosis documented within the prior 730 days

    Initial antineoplastic-agent authorization

    Initial authorization requires both documented steps.

    Qualifying diagnosis and prior therapy

    • Malignant cancer diagnosis: A diagnosis from the listed Malignant Cancer Diagnosis Codes is present.
    • Antineoplastic-agent history: At least one listed antineoplastic agent was used during the look-back period.1 agent within 365 days

    Initial authorization sequential requirements

    Initial authorization requires both sequential steps.

    Initial authorization

    • Prior therapy: History of one listed antineoplastic agent.1 agent within 365 days
    • Diagnosis: One listed CNMP ICD-10 diagnosis.1 diagnosis within 365 days